>
Venus Medtech Hangzhou Inc logo

2500 - Venus Medtech Hangzhou Inc Share Price

HK$39.5 -0.3  -0.8%

Last Trade - 21/09/21

Market Cap £1.71bn
Enterprise Value £1.31bn
Revenue £46.8m
Position in Universe 653rd / 6157
Bullish
Bearish
Unlock 2500 Revenue
Momentum
Relative Strength (%)
1m +4.21%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -59.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
242.7
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 18.2 115.3 233.3 276 560.1 1,019 +147.7%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2021, Venus MedTechHangZhou Inc revenues increased from RMB102M to RMB239.3M.Net loss increased from RMB43.5M to RMB113.1M. Revenuesreflect an increase in demand for the Company's productsand services due to favorable market conditions. Higher netloss reflects Other expenses increase from RMB20.4M toRMB81.3M (expense), Selling and distribution expensesincrease from RMB47.2M to RMB99.1M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for 2500
Graphical History

Revenue

2500 Revenue Unlock 2500 Revenue

Net Income

2500 Net Income Unlock 2500 Revenue

Normalised EPS

2500 Normalised EPS Unlock 2500 Revenue

PE Ratio Range

2500 PE Ratio Range Unlock 2500 Revenue

Dividend Yield Range

2500 Dividend Yield Range Unlock 2500 Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
2500 EPS Forecasts Unlock 2500 Revenue
Profile Summary

Venus MedTech (HangZhou) Inc. is a China-based company engaged in the research, development, manufacture and sales of minimally invasive medical devices and auxiliary instruments and equipment for the treatment of heart valve diseases. The Company's main products include the VenusA-Valve System, VenusA-Plus System, VenusA-Pilot System, VenusP-Valve System, TMVR valve, TTVR valve, valvuloplasty balloons V8 / TAV8 and TriGUARD3 Cerebral Embolic Protection Device.

Directors
Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated July 3, 2009
Public Since December 10, 2019
No. of Shareholders: n/a
No. of Employees: 514
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Hang Seng Composite , Hang Seng Composite LargeCap & MidCap , Hang Seng Composite MidCap , Hang Seng Composite Mid & SmallCap ,
Exchange Stock Exchange of Hong Kong Limited
Shares in Issue 459,617,015
Free Float (0.0%)
Eligible for
ISAs
SIPPs
+
Address , HANGZHOU, China
Web http://www.venusmedtech.com
Phone +
Contact ()
Auditors Ernst & Young
2500 Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for 2500
Upcoming Events for 2500
Frequently Asked Questions for Venus Medtech Hangzhou Inc
What is the Venus Medtech Hangzhou Inc share price?

As of 21/09/21, shares in Venus Medtech Hangzhou Inc are trading at HK$39.5, giving the company a market capitalisation of £1.71bn. This share price information is delayed by 15 minutes.

How has the Venus Medtech Hangzhou Inc share price performed this year?

Shares in Venus Medtech Hangzhou Inc are currently trading at HK$39.5 and the price has moved by -52.05% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Venus Medtech Hangzhou Inc price has moved by -60.91% over the past year.

What are the analyst and broker recommendations for Venus Medtech Hangzhou Inc?

There are no analysts currently covering Venus Medtech Hangzhou Inc.

When will Venus Medtech Hangzhou Inc next release its financial results?

Venus Medtech Hangzhou Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the Venus Medtech Hangzhou Inc dividend yield?

Venus Medtech Hangzhou Inc does not currently pay a dividend.

Does Venus Medtech Hangzhou Inc pay a dividend?

Venus Medtech Hangzhou Inc does not currently pay a dividend.

When does Venus Medtech Hangzhou Inc next pay dividends?

Venus Medtech Hangzhou Inc does not currently pay a dividend.

How do I buy Venus Medtech Hangzhou Inc shares?

To buy shares in Venus Medtech Hangzhou Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Venus Medtech Hangzhou Inc?

Shares in Venus Medtech Hangzhou Inc are currently trading at HK$39.5, giving the company a market capitalisation of £1.71bn.

Where are Venus Medtech Hangzhou Inc shares listed? Where are Venus Medtech Hangzhou Inc shares listed?

Here are the trading details for Venus Medtech Hangzhou Inc:

Country of listing: Hong Kong
Exchange: HKG
Ticker Symbol: 2500
What kind of share is Venus Medtech Hangzhou Inc?

Based on an overall assessment of its quality, value and momentum, Venus Medtech Hangzhou Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Venus Medtech Hangzhou Inc share price forecast 2021?

Shares in Venus Medtech Hangzhou Inc are currently priced at HK$39.5. At that level they are trading at 66.28% discount to the analyst consensus target price of 0.00.

Analysts covering Venus Medtech Hangzhou Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.2718922552 for the next financial year.

How can I tell whether the Venus Medtech Hangzhou Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Venus Medtech Hangzhou Inc. Over the past six months, the relative strength of its shares against the market has been -33.07%. At the current price of HK$39.5, shares in Venus Medtech Hangzhou Inc are trading at -39.23% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Venus Medtech Hangzhou Inc PE Ratio?

We were not able to find PE ratio data for Venus Medtech Hangzhou Inc.

Who are the key directors of Venus Medtech Hangzhou Inc?

Venus Medtech Hangzhou Inc's management team is headed by:

Min Frank Zeng - CHM
Zhenjun Zi - GMG
Hou-Sen Lim - COO
Wing-Yu Leung - NVC
Ting Yuk Wu - NID
Wan Yee Lau - NID
Chi Wai Suen - NID
Haiyue Ma - CFO
Christopher Lee Richardson - OTH
Wai Chiu Wong - SEC
Who are the major shareholders of Venus Medtech Hangzhou Inc?

Here are the top five shareholders of Venus Medtech Hangzhou Inc based on the size of their shareholding:

Qiming Venture Partners Venture Capital
Percentage owned: 13.33% (58.8m shares)
GIC Private Limited Sovereign Wealth Fund
Percentage owned: 9.07% (40.0m shares)
Zeng (Min Frank) Individual Investor
Percentage owned: 7.63% (33.7m shares)
Zi (Zhenjun) Individual Investor
Percentage owned: 7.3% (32.2m shares)
JPMorgan Asset Management (Asia Pacific) Limited Investment Advisor/Hedge Fund
Percentage owned: 2.22% (9.80m shares)
Similar to 2500
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.